Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1

Published:2020-10 Issue:10 Volume:10 Page:1943-1953
ISSN:2211-3835
Container-title:Acta Pharmaceutica Sinica B
language:en
Short-container-title:Acta Pharmaceutica Sinica B

Author:

Hu Mingxing,Zhou Weilin,Wang Yijie,Yao Dongping,Ye Tinghong,Yao Yuqin,Chen Bin,Liu Gongping,Yang Xifei,Wang Wei,Xie Yongmei

Publisher

Elsevier BV

Subject

General Pharmacology, Toxicology and Pharmaceutics

Reference40 articles.

1. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion;Platten;Canc Res,2012

2. Prevention of allogeneic fetal rejection by tryptophan catabolism;Munn;Science,1998

3. Indoleamine 2,3-dioxygenase: distribution and function in the developing human placenta;Yoshiki;J Reprod Immunol,2004

4. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives;Godin-Ethier;Clin Canc Res,2011

5. Tumor immune escape mediated by indoleamine 2,3-dioxygenase;Zamanakou;Immunol Lett,2007

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small-molecule in cancer immunotherapy: Revolutionizing cancer treatment with transformative, game-changing breakthroughs;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Monovalent Pseudo-Natural Product Degraders Supercharge the Native Degradation of IDO1 by KLHDC3;2024-07-13

3. Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions;Bioconjugate Chemistry;2024-07-11

4. CAR-T therapy and targeted treatments: Emerging combination strategies in solid tumors;Med;2024-06

5. Glioblastoma Therapy: Past, Present and Future;International Journal of Molecular Sciences;2024-02-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3